Targeting iNKT cells for the treatment of sickle cell disease

Clinical Immunology

Volumn 140, Issue 2, 2011, Pages 177-183

  Field, Joshua J ^a   Nathan, David G ^b   Linden, Joel ^c  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

INKT cells; Regadenoson; Sickle cell disease

Indexed keywords

ADENOSINE; ADENOSINE A2 RECEPTOR; ADENOSINE B2 RECEPTOR; ADENOSINE RECEPTOR; APADENOSON; CD1D ANTIGEN; REGADENOSON; UNCLASSIFIED DRUG;

ACUTE CHEST SYNDROME; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DOSE CALCULATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HEART INJURY; HUMAN; HYPOTENSION; INTESTINE INJURY; INVARIANT NATURAL KILLER CELL; KIDNEY INJURY; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; LIVER INJURY; LUNG INJURY; LYMPHOCYTE ACTIVATION; MICROVASCULAR ENDOTHELIAL CELL; NATURAL KILLER CELL; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REPERFUSION INJURY; REVIEW; RISK REDUCTION; SICKLE CELL ANEMIA; SKIN INJURY; TACHYCARDIA; THROMBOCYTE ACTIVATION;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANEMIA, SICKLE CELL; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; LYMPHOCYTE ACTIVATION; MICE; NATURAL KILLER T-CELLS; PURINES; PYRAZOLES;

EID: 79960442267     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.03.002     Document Type: Review

References (57)

1. Platt O.S., Thorington B.D., Brambilla D.J., Milner P.F., Rosse W.F., Vichinsky E., Kinney T.R. Pain in sickle cell disease. Rates and risk factors. N. Engl. J. Med. 1991, 325:11-16.
2. Castro O., Brambilla D.J., Thorington B., Reindorf C.A., Scott R.B., Gillette P., Vera J.C., Levy P.S. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994, 84:643-649.
3. Goldberg M.A., Brugnara C., Dover G.J., Schapira L., Charache S., Bunn H.F. Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N. Engl. J. Med. 1990, 323:366-372.
4. Chang J., Shi P.A., Chiang E.Y., Frenette P.S. Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. Blood 2008, 111:915-923.
5. Chang J., Patton J.T., Sarkar A., Ernst B., Magnani J.L., Frenette P.S. GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice. Blood 2010, 116:1779-1786.
6. Reiter C.D., Wang X., Tanus-Santos J.E., Hogg N., Cannon R.O., Schechter A.N., Gladwin M.T. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat. Med. 2002, 8:1383-1389.
7. Kono H., Rock K.L. How dying cells alert the immune system to danger. Nat. Rev. Immunol. 2008, 8:279-289.
8. McDonald B., Pittman K., Menezes G.B., Hirota S.A., Slaba I., Waterhouse C.C., Beck P.L., Muruve D.A., Kubes P. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 2010, 330:362-366.
9. Darmoise A., Teneberg S., Bouzonville L., Brady R.O., Beck M., Kaufmann S.H., Winau F. Lysosomal alpha-galactosidase controls the generation of self lipid antigens for natural killer T cells. Immunity 2010, 33:216-228.
10. Kaul D.K., Hebbel R.P. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J. Clin. Invest. 2000, 106:411-420.
11. Pritchard K.A., Ou J., Ou Z., Shi Y., Franciosi J.P., Signorino P., Kaul S., Ackland-Berglund C., Witte K., Holzhauer S., Mohandas N., Guice K.S., Oldham K.T., Hillery C.A. Hypoxia-induced acute lung injury in murine models of sickle cell disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 286:L705-L714.
12. Turhan A., Weiss L.A., Mohandas N., Coller B.S., Frenette P.S. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc. Natl Acad. Sci. U.S.A. 2002, 99:3047-3051.
13. Oury C., Toth-Zsamboki E., Vermylen J., Hoylaerts M.F. The platelet ATP and ADP receptors. Curr. Pharm. Des. 2006, 12:859-875.
14. Marcondes S., Cardoso M.H., Morganti R.P., Thomazzi S.M., Lilla S., Murad F., De Nucci G., Antunes E. Cyclic GMP-independent mechanisms contribute to the inhibition of platelet adhesion by nitric oxide donor: a role for alpha-actinin nitration. Proc. Natl Acad. Sci. U.S.A. 2006, 103:3434-3439.
15. Brittain H.A., Eckman J.R., Swerlick R.A., Howard R.J., Wick T.M. Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: a potential role for platelet activation in sickle cell vaso-occlusion. Blood 1993, 81:2137-2143.
16. Inwald D.P., Kirkham F.J., Peters M.J., Lane R., Wade A., Evans J.P., Klein N.J. Platelet and leucocyte activation in childhood sickle cell disease: association with nocturnal hypoxaemia. Br. J. Haematol. 2000, 111:474-481.
17. Polanowska-Grabowska R., Wallace K., Field J.J., Chen L., Marshall M.A., Figler R., Gear A.R., Linden J. P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease. Arterioscler. Thromb. Vasc. Biol. 2010, 30:2392-2399.
18. Bernini J.C., Rogers Z.R., Sandler E.S., Reisch J.S., Quinn C.T., Buchanan G.R. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood 1998, 92:3082-3089.
19. Alchera E., Tacchini L., Imarisio C., Dal Ponte C., De Ponti C., Gammella E., Cairo G., Albano E., Carini R. Adenosine-dependent activation of hypoxia-inducible factor-1 induces late preconditioning in liver cells. Hepatology 2008, 48:230-239.
20. Ben-Ari Z., Pappo O., Sulkes J., Cheporko Y., Vidne B.A., Hochhauser E. Effect of adenosine A2A receptor agonist (CGS) on ischemia/reperfusion injury in isolated rat liver. Apoptosis 2005, 10:955-962.
21. Cao Z., Yuan Y., Jeyabalan G., Du Q., Tsung A., Geller D.A., Billiar T.R. Preactivation of NKT cells with alpha-GalCer protects against hepatic ischemia-reperfusion injury in mouse by a mechanism involving IL-13 and adenosine A2A receptor. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 297:G249-G258.
22. Day Y.J., Li Y., Rieger J.M., Ramos S.I., Okusa M.D., Linden J. A2A adenosine receptors on bone marrow-derived cells protect liver from ischemia-reperfusion injury. J. Immunol. 2005, 174:5040-5046.
23. Day Y.J., Marshall M.A., Huang L., McDuffie M.J., Okusa M.D., Linden J. Protection from ischemic liver injury by activation of A2A adenosine receptors during reperfusion: inhibition of chemokine induction. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 286:G285-G293.
24. Harada N., Okajima K., Murakami K., Usune S., Sato C., Ohshima K., Katsuragi T. Adenosine and selective A(2A) receptor agonists reduce ischemia/reperfusion injury of rat liver mainly by inhibiting leukocyte activation. J. Pharmacol. Exp. Ther. 2000, 294:1034-1042.
25. Day Y.J., Huang L., McDuffie M.J., Rosin D.L., Ye H., Chen J.F., Schwarzschild M.A., Fink J.S., Linden J., Okusa M.D. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J. Clin. Invest. 2003, 112:883-891.
26. Day Y.J., Huang L., Ye H., Linden J., Okusa M.D. Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: role of macrophages. Am. J. Physiol. Ren. Physiol. 2005, 288:F722-F731.
27. Okusa M.D., Linden J., Huang L., Rosin D.L., Smith D.F., Sullivan G. Enhanced protection from renal ischemia-reperfusion [correction of ischemia:reperfusion] injury with A(2A)-adenosine receptor activation and PDE 4 inhibition. Kidney Int. 2001, 59:2114-2125.
28. Okusa M.D., Linden J., Macdonald T., Huang L. Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney. Am. J. Physiol. 1999, 277:F404-F412.
29. Peirce S.M., Skalak T.C., Rieger J.M., Macdonald T.L., Linden J. Selective A(2A) adenosine receptor activation reduces skin pressure ulcer formation and inflammation. Am. J. Physiol. Heart Circ. Physiol. 2001, 281:H67-H74.
30. Sharma A.K., Laubach V.E., Ramos S.I., Zhao Y., Stukenborg G., Linden J., Kron I.L., Yang Z. Adenosine A2A receptor activation on CD4+ T lymphocytes and neutrophils attenuates lung ischemia-reperfusion injury. J. Thorac. Cardiovasc. Surg. 2010, 139:474-482.
31. Gazoni L.M., Laubach V.E., Mulloy D.P., Bellizzi A., Unger E.B., Linden J., Ellman P.I., Lisle T.C., Kron I.L. Additive protection against lung ischemia-reperfusion injury by adenosine A2A receptor activation before procurement and during reperfusion. J. Thorac. Cardiovasc. Surg. 2008, 135:156-165.
32. Rivo J., Zeira E., Galun E., Einav S., Linden J., Matot I. Attenuation of reperfusion lung injury and apoptosis by A2A adenosine receptor activation is associated with modulation of Bcl-2 and Bax expression and activation of extracellular signal-regulated kinases. Shock 2007, 27:266-273.
33. Xi J., McIntosh R., Shen X., Lee S., Chanoit G., Criswell H., Zvara D.A., Xu Z. Adenosine A2A and A2B receptors work in concert to induce a strong protection against reperfusion injury in rat hearts. J. Mol. Cell. Cardiol. 2009, 47:684-690.
34. Rork T.H., Wallace K.L., Kennedy D.P., Marshall M.A., Lankford A.R., Linden J. Adenosine A2A receptor activation reduces infarct size in the isolated, perfused mouse heart by inhibiting resident cardiac mast cell degranulation. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H1825-H1833.
35. Yang Z., Day Y.J., Toufektsian M.C., Xu Y., Ramos S.I., Marshall M.A., French B.A., Linden J. Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes. Circulation 2006, 114:2056-2064.
36. Patel R.A., Glover D.K., Broisat A., Kabul H.K., Ruiz M., Goodman N.C., Kramer C.M., Meerdink D.J., Linden J., Beller G.A. Reduction in myocardial infarct size at 48hours after brief intravenous infusion of ATL-146e, a highly selective adenosine A2A receptor agonist. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H637-H642.
37. Di Paola R., Melani A., Esposito E., Mazzon E., Paterniti I., Bramanti P., Pedata F., Cuzzocrea S. Adenosine A2A receptor-selective stimulation reduces signaling pathways involved in the development of intestine ischemia and reperfusion injury. Shock 2010, 33:541-551.
38. Reece T.B., Tribble C.G., Okonkwo D.O., Davis J.D., Maxey T.S., Gazoni L.M., Linden J., Kron I.L., Kern J.A. Early adenosine receptor activation ameliorates spinal cord reperfusion injury. J. Cardiovasc. Med. 2008, 9:363-367. (Hagerstown).
39. Li Y., Oskouian R.J., Day Y.J., Rieger J.M., Liu L., Kern J.A., Linden J. Mouse spinal cord compression injury is reduced by either activation of the adenosine A2A receptor on bone marrow-derived cells or deletion of the A2A receptor on non-bone marrow-derived cells. Neuroscience 2006, 141:2029-2039.
40. Cassada D.C., Tribble C.G., Young J.S., Gangemi J.J., Gohari A.R., Butler P.D., Rieger J.M., Kron I.L., Linden J., Kern J.A. Adenosine A2A analogue improves neurologic outcome after spinal cord trauma in the rabbit. J. Trauma 2002, 53:225-229. discussion 229-31.
41. Sullivan G.W., Fang G., Linden J., Scheld W.M. A2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis. J. Infect. Dis. 2004, 189:1897-1904.
42. Murphree L.J., Sullivan G.W., Marshall M.A., Linden J. Lipopolysaccharide rapidly modifies adenosine receptor transcripts in murine and human macrophages: role of NF-kappaB in A(2A) adenosine receptor induction. Biochem. J. 2005, 391:575-580.
43. Reutershan J., Cagnina R.E., Chang D., Linden J., Ley K. Therapeutic anti-inflammatory effects of myeloid cell adenosine receptor A2a stimulation in lipopolysaccharide-induced lung injury. J. Immunol. 2007, 179:1254-1263.
44. Zhai Y., Shen X.D., Hancock W.W., Gao F., Qiao B., Lassman C., Belperio J.A., Strieter R.M., Busuttil R.W., Kupiec-Weglinski J.W. CXCR3+ CD4+ T cells mediate innate immune function in the pathophysiology of liver ischemia/reperfusion injury. J. Immunol. 2006, 176:6313-6322.
45. Shimamura K., Kawamura H., Nagura T., Kato T., Naito T., Kameyama H., Hatakeyama K., Abo T. Association of NKT cells and granulocytes with liver injury after reperfusion of the portal vein. Cell. Immunol. 2005, 234:31-38.
46. Lappas C.M., Day Y.J., Marshall M.A., Engelhard V.H., Linden J. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J. Exp. Med. 2006, 203:2639-2648.
47. Lee H.H., Meyer E.H., Goya S., Pichavant M., Kim H.Y., Bu X., Umetsu S.E., Jones J.C., Savage P.B., Iwakura Y., Casasnovas J.M., Kaplan G., Freeman G.J., DeKruyff R.H., Umetsu D.T. Apoptotic cells activate NKT cells through T cell Ig-like mucin-like-1 resulting in airway hyperreactivity. J. Immunol. 2010, 185:5225-5235.
48. Wallace K.L., Marshall M.A., Ramos S.I., Lannigan J.A., Field J.J., Strieter R.M., Linden J. NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines. Blood 2009, 114:667-676.
49. Wallace K.L., Linden J. Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease. Blood 2010.
50. Hocher B. Adenosine A1 receptor antagonists in clinical research and development. Kidney Int. 2010, 78:438-445.
51. Mi T., Abbasi S., Zhang H., Uray K., Chunn J.L., Xia L.W., Molina J.G., Weisbrodt N.W., Kellems R.E., Blackburn M.R., Xia Y. Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling. J. Clin. Invest. 2008, 118:1491-1501.
52. Wen J., Jiang X., Dai Y., Zhang Y., Tang Y., Sun H., Mi T., Phatarpekar P.V., Kellems R.E., Blackburn M.R., Xia Y. Increased adenosine contributes to penile fibrosis, a dangerous feature of priapism, via A2B adenosine receptor signaling. FASEB J. 2010, 24:740-749.
53. Zhang Y., Dai Y., Wen J., Zhang W., Grenz A., Sun H., Tao L., Lu G., Alexander D.C., Milburn M.V., Carter-Dawson L., Lewis D.E., Eltzschig H.K., Kellems R.E., Blackburn M.R., Juneja H.S., Xia Y. Detrimental effects of adenosine signaling in sickle cell disease. Nat. Med. 2011, 17:79-86.
54. Exley M.A., Hou R., Shaulov A., Tonti E., Dellabona P., Casorati G., Akbari O., Akman H.O., Greenfield E.A., Gumperz J.E., Boyson J.E., Balk S.P., Wilson S.B. Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop. Eur. J. Immunol. 2008, 38:1756-1766.
55. Lombardi V., Stock P., Singh A.K., Kerzerho J., Yang W., Sullivan B.A., Li X., Shiratsuchi T., Hnatiuk N.E., Howell A.R., Yu K.O., Porcelli S.A., Tsuji M., Kronenberg M., Wilson S.B., Akbari O. A CD1d-dependent antagonist inhibits the activation of invariant NKT cells and prevents development of allergen-induced airway hyperreactivity. J. Immunol. 2010, 184:2107-2115.
56. Felio K., Nguyen H., Dascher C.C., Choi H.J., Li S., Zimmer M.I., Colmone A., Moody D.B., Brenner M.B., Wang C.R. CD1-restricted adaptive immune responses to Mycobacteria in human group 1 CD1 transgenic mice. J. Exp. Med. 2009, 206:2497-2509.
57. Arrenberg P., Halder R., Kumar V. Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens. J. Cell. Physiol. 2009, 218:246-250.